Avantor, Inc.

AVTR Healthcare Medical Instruments & Supplies

Avantor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.6 billion, down 3.41% from fiscal 2024.

Revenue
+4.59%
EPS
+128.9%
Free cash flow
−9.03%
Total debt
−4.51%

Quarter to September 2026, against a year earlier

15.38 0.24 +1.59%
Market cap
$10.3B
P/E
30.3×
Fwd P/E
34.8×
Dividend yield
—
F-score
4/9
Altman Z
1.55
Beneish M
−2.91
Dividend safety
n/a

Avantor, Inc. 10-K filed Feb 11, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 7:34 AM ET · Document on sec.gov · Filing index

What changed

Item 1, Business, against the 10-K filed Feb 7, 2025: 7 added · 1 removed · 24 modified; 6 with only figures updated

  1. Modified

    We are a leading global provider of mission-critical products and services to customers in the biopharma, & healthcare, education & government, and advanced technologies & applied materials industriesend markets. Our business model is grounded in supporting our customers from discovery to delivery and Avantor is embedded in virtually every stage of the most important research, scale-up and manufacturing activities in the industries we serve.